[Therapy of supraventricular arrhythmias with a cardioselective beta-receptor blocker (tolamolol)].
In order to evaluate the effect of a new cardioselective beta-blocker (tolamolol) on supraventricular tachyarrhythmias, 10-30 mg of tolamolol was administered on 38 occasions to 35 patients. It is concluded that tolamolol reduces ventricular rate in supraventricular tachyarrhythmias and is often effective in converting paroxysmal atrial fibrillation to sinus rhythm.
D004341:Drug Evaluation; D006801:Humans; D011412:Propanolamines / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy
D011412:Propanolamines
Therapie supreventrikulärer Rhythmusstörungen mit einem kardioselektiven beta-Rezeptoren-Blocker (Tolamolol)